OPKO Health, Inc. (NYSE: OPK) announced that is has completed the acquisition of Silcon Comércio, Importacao E Exportacao de Produtos Farmaceuticos e Cosmeticos Ltda.

Domiciled in Sao Paulo, Brazil, Silcon expands OPKO's presence in Latin America and complements business activities of units in Chile and Mexico, as well as permits commercialization of the OPKO 4KScore prostate cancer test in Brazil as a reference laboratory test while OPKO obtains local approval to market its point of care microfluidics disposable test cassettes.

Phillip Frost, M.D., OPKO's Chairman and Chief Executive Officer, commented, "We are excited to establish our initial footprint in the most important growth market in South America and initiate commercial efforts towards the introduction of our 4Kscore test in the Brazilian market."